Advertisement
Atea Pharmaceuticals, Inc. (AVIR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 3.2500 |
| Open | 3.2700 |
| Bid | 3.3200 x 100 |
| Ask | 3.4100 x 100 |
| Day's Range | 3.2350 - 3.3880 |
| 52 Week Range | 2.8100 - 4.6000 |
| Volume | |
| Avg. Volume | 192,535 |
| Market Cap | 284.641M |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0700 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.89 |
ZacksIs Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
GlobeNewswireAtea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor,
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.